Mounjaro Side Effects: What Is Common and What Is Rare
Mounjaro side effects mostly hit the gut. On its US label, nausea, diarrhea and five other stomach or appetite effects are the common ones, and some people given placebo in the same trials had them too. Some serious problems on the label, such as pancreatitis, were rare in the trials. Others, such as kidney injury, come from reports after approval and have no known rate.
Mounjaro is the brand name for tirzepatide. As of 20 November 2026 it is approved in the US, by prescription, with diet and exercise, for blood sugar control in adults and children 10 and older with type 2 diabetes. A second approved use is lowering the chance of a heart attack, stroke or heart death in high risk adults who have type 2 diabetes. It is not approved for weight management. This page reads its side effects straight from the label, with each rate tied to the trials it came from.
On this page
Mounjaro side effects at a glance
Five facts frame everything below. The numbers come from one place, the label Eli Lilly files with the FDA.
| Point | Mounjaro |
|---|---|
| Medicine | Mounjaro, whose active ingredient is tirzepatide (acts on GIP and GLP-1 receptors) |
| Label read | Eli Lilly US label, version 40, effective 27 August 2026, re-read 20 November 2026 |
| Main side effect table | Two placebo controlled trials, SURPASS-1 and SURPASS-5, in adults with type 2 diabetes |
| Most common type | Gut side effects, also seen in about 20 in 100 people on placebo |
| Boxed warning | Thyroid C-cell tumors in rats. Unknown in humans |
Mounjaro first won FDA approval on 13 May 2022 as a new molecule. The use in children 10 and older was added in December 2025. Its US label is the source for every rate on this page.
Sources: Mounjaro US label, Eli Lilly, effective 27 Aug 2026 (DailyMed); Mounjaro approvals, Drugs@FDA (openFDA)
What kinds of side effects does the label list?
Three kinds, and each is counted in a different way. Think of them as three shelves. The common shelf has firm rates from placebo controlled trials. The warning shelf holds serious problems: some have trial rates, and some come only from reports after approval with no known rate. The last shelf holds reports sent in after approval, which have no rate at all.
| Shelf | What is on it | How often | Where the number comes from |
|---|---|---|---|
| Common | Nausea, diarrhea, vomiting, constipation, decreased appetite, belly pain, indigestion | Each in at least 5 in 100 people on Mounjaro in the Table 1 trials | Label Table 1, placebo controlled |
| Serious warnings | Pancreatitis, gallbladder disease, severe gut reactions, kidney injury, low blood sugar, allergic reactions, eye changes in diabetic retinopathy, aspiration during anesthesia | Some had trial rates under 1 in 100; others come from reports after approval with no rate | Label Warnings section |
| Voluntary reports | Bowel blockage (ileus), severe constipation, hair loss and more | Unknown. The label says these reports cannot give a reliable rate or prove the drug caused them | Label, postmarketing section |
Above all three sits a boxed warning. It is about thyroid tumors in rats, and it has its own section further down.
Sources: Mounjaro US label, Eli Lilly, effective 27 Aug 2026 (DailyMed)
What are the common Mounjaro side effects?
Seven, and six of them are in the gut. The label pools two placebo controlled trials, SURPASS-1 and SURPASS-5, in adults with type 2 diabetes. In them, 718 people took Mounjaro for an average of 36.6 weeks and 235 took placebo, a dummy treatment used for comparison. Each side effect below showed up in at least 5 in 100 people on Mounjaro.
| Side effect | Placebo | Mounjaro | Extra above placebo |
|---|---|---|---|
| Nausea | 4 | 12 to 18 | 8 to 14 |
| Diarrhea | 9 | 12 to 17 | 3 to 8 |
| Decreased appetite | 1 | 5 to 11 | 4 to 10 |
| Vomiting | 2 | 5 to 9 | 3 to 7 |
| Constipation | 1 | 6 to 7 | 5 to 6 |
| Indigestion (dyspepsia) | 3 | 5 to 8 | 2 to 5 |
| Belly (abdominal) pain | 4 | 5 to 6 | 1 to 2 |
The placebo column matters. Nine in 100 people on placebo had diarrhea, so not every case on Mounjaro is caused by the drug. The extra column shows the gap. Nausea has the biggest gap. Belly pain has the smallest.
Counting any gut side effect at all, about 20 in 100 people on placebo had one, against 37 to 44 in 100 on Mounjaro. Stopping treatment because of gut effects happened in 3.0 to 6.6 percent on Mounjaro and 0.4 percent on placebo. Smaller gut effects also rose above placebo: burping, gas and acid reflux each reached about 1 to 3 in 100.
The SURPASS-1 report itself described the most frequent side effects as mild to moderate, short lived gut events. A wider look at this whole drug class is on our GLP-1 side effects guide.
Sources: Mounjaro US label, Eli Lilly, effective 27 Aug 2026 (DailyMed); SURPASS-1, Lancet 2021 (PMID 34186022)
Do Mounjaro gut side effects fade?
In the trials, mostly yes. The Mounjaro label says most nausea, vomiting and diarrhea reports came early, while treatment was being stepped up, and then became less common. That describes the trial groups as a whole, not what any one person will feel.
The label also notes that tirzepatide slows stomach emptying most at the very start, and that this effect shrinks over time. It does not say the slowing causes the nausea, so this page treats it only as a possible link. What the molecule does in the gut and brain is covered on our how tirzepatide works page.
Sources: Mounjaro US label, Eli Lilly, effective 27 Aug 2026 (DailyMed)
What are the serious Mounjaro side effects?
The label lists several serious warnings, and they are not all counted the same way. Pancreatitis, gallbladder problems, severe gut reactions and allergic reactions have rates from the trials, shown below. Kidney injury and the anesthesia problem come only from reports made after approval, so they have no known rate. For low blood sugar and the retinopathy warning, this page does not quote a rate.
- Pancreatitis, an inflamed pancreas, was rare. In the clinical studies there were 0.23 patients per 100 years of exposure on Mounjaro versus 0.11 on comparison treatments. Patient years stack everyone's time on treatment into one pile. Its warning sign in the Medication Guide is severe pain in the stomach area that does not go away. For that sign, the guide tells people to stop using Mounjaro and call a healthcare provider right away.
- Gallbladder problems, such as gallstones, were rare: 0.6 percent on Mounjaro and 0 percent on placebo in the placebo controlled trials.
- Severe gut reactions were uncommon, from 0.4 to 1.3 percent on Mounjaro against 0.9 percent on placebo. The label says they happened more often on Mounjaro overall, and it does not recommend Mounjaro for severe gastroparesis, a very slow stomach.
- Kidney injury was reported after approval, sometimes needing dialysis. Most of those people had lost fluid through nausea, vomiting or diarrhea.
- Low blood sugar risk is tied mainly to use alongside insulin or a sulfonylurea, an older type of diabetes pill.
- Allergic reactions, sometimes severe, were reported in 3.2 percent on Mounjaro and 1.7 percent on placebo. Serious ones, including anaphylaxis, have been reported.
- Eye changes: in people with diabetic retinopathy, temporary worsening has been reported with fast drops in blood sugar. This warning was updated in August 2026. Separately, on 9 November 2026 the FDA told makers of all GLP-1 drugs, Mounjaro included, to add a warning about a possible higher risk of NAION, a rare condition where blood flow to the optic nerve drops and sight can be lost suddenly in one eye. In the FDA's pooled look at 126 trials, it happened in 6.4 people per 100,000 years of use on these drugs, against 3.8 on placebo or other diabetes drugs. The FDA tells people to contact their health care professional right away about sudden vision loss. The label we read, dated August 2026, does not carry this warning yet.
- Anesthesia: rare reports describe stomach contents reaching the lungs during general anesthesia or deep sedation in people on GLP-1 drugs. The label asks people to tell providers before any planned surgery or procedure.
The label also records a small rise in average heart rate, 2 to 4 beats per minute on Mounjaro against 1 on placebo, and says its meaning is uncertain. On the third shelf, voluntary reports after approval include bowel blockage, severe constipation and hair loss.
Sources: Mounjaro US label, Eli Lilly, effective 27 Aug 2026 (DailyMed); FDA Drug Safety Communication on GLP-1 drugs and NAION, 9 Nov 2026
Why does Mounjaro have a boxed warning about thyroid tumors?
Because of rat studies. In a two year study, rats of both sexes on tirzepatide grew more thyroid C-cell tumors, and the rise was bigger with more drug and longer treatment. A second animal study, six months long in specially bred mice, found tirzepatide was not tumor forming. Both are animal data.
The label says it is unknown whether tirzepatide causes these tumors in humans, including medullary thyroid carcinoma. It says people who have had that cancer, or whose family has, and people with MEN 2, the inherited disorder multiple endocrine neoplasia type 2, must not use it. The Medication Guide names four signs to raise with a provider: a neck lump or swelling, a hoarse voice, trouble swallowing, and shortness of breath.
The label adds that routine calcitonin blood tests or thyroid ultrasound are of uncertain value for catching this cancer early in people on Mounjaro.
Sources: Mounjaro US label, Eli Lilly, effective 27 Aug 2026 (DailyMed)
How should you read Mounjaro side effect rates?
As trial averages for a certain group. The Table 1 numbers come from adults with type 2 diabetes, so they describe those people. A larger pool of seven controlled trials, with 5,119 adults, found common side effects of a similar type and frequency. The label warns that these rates are not directly comparable to those in other drugs' trials, and could differ from real-world use. That is why this page makes no claim that Mounjaro has more or fewer side effects than another drug; the trial design questions are covered on our semaglutide vs tirzepatide page.
Children are a separate group. The label says children 10 and older had side effects like adults, except for more vomiting, belly pain and low blood sugar. In the 30 week placebo controlled part of that trial, vomiting was 3 percent on placebo and 12 to 16 percent on Mounjaro, and belly pain 9 percent versus 15 to 22 percent.
Zepbound, the same molecule, has its own label because it is approved for other uses: weight reduction in certain adults, and obstructive sleep apnea of moderate to severe degree in adults living with obesity. Its side effect table comes from different trials. Why one molecule has two US brand names is on our page is tirzepatide the same as Mounjaro.
Sources: Mounjaro US label, Eli Lilly, effective 27 Aug 2026 (DailyMed); Zepbound US label, Eli Lilly, effective 28 Aug 2026 (DailyMed)
What else do people ask about Mounjaro side effects?
What are the most common Mounjaro side effects?+
The US label lists seven, each seen in at least 5 percent of people on Mounjaro in two placebo controlled trials. In order they are nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion (dyspepsia) and belly pain. Six of the seven are gut effects.
Do Mounjaro side effects go away?+
The label says most reports of nausea, vomiting and diarrhea came early, while treatment was being stepped up, and became less common over time. It does not promise that they fade for every person.
How many people stopped Mounjaro because of side effects?+
In the label pool of two placebo controlled trials, 3.0 to 6.6 percent of people on Mounjaro stopped because of gut side effects, compared with 0.4 percent on placebo.
Is pancreatitis common on Mounjaro?+
No. The label calls it a serious warning, but it was rare: 0.23 patients per 100 years of exposure on Mounjaro versus 0.11 on comparison treatments in the clinical studies.
Does Mounjaro cause thyroid cancer?+
The label says it is unknown. Its boxed warning comes from a two year rat study that found more thyroid C-cell tumors. A six month study in specially bred mice found it was not tumor forming. Both are animal results.
Can Mounjaro cause hair loss?+
Hair loss is on the label list of voluntary reports made after approval. Those reports have no known rate, and the label says they cannot prove the drug caused it.
Does Mounjaro cause low blood sugar?+
The label ties the risk mainly to using it with insulin or a sulfonylurea, another kind of diabetes medicine. In the trial where Mounjaro was the only diabetes drug, no one in any group had severe low blood sugar.
Are Mounjaro side effects different in children?+
The label says children 10 and older had side effects like adults, except for more vomiting, belly pain and low blood sugar. In the 30 week placebo controlled part, vomiting was 3 percent on placebo and 12 to 16 percent on Mounjaro.
Sources: Mounjaro US label, Eli Lilly, effective 27 Aug 2026 (DailyMed); Mounjaro label record, openFDA
What did we learn about Mounjaro side effects?
The common ones are gut effects that rose above placebo, and most nausea, vomiting and diarrhea came early. Pancreatitis and gallbladder problems were rare, severe gut reactions were uncommon, and the boxed warning rests on rat studies whose meaning for people is unknown.
Molecule Mechanics turns the science of molecules into short animations, with sources below each video. Every rate here was read from the Mounjaro and Zepbound US labels, Drugs@FDA and the SURPASS-1 report on 20 November 2026, following our medical review policy.
If any fact here looks wrong, our corrections policy explains how to tell us.
Sources: Mounjaro US label, Eli Lilly, effective 27 Aug 2026 (DailyMed); Zepbound US label, Eli Lilly, effective 28 Aug 2026 (DailyMed); Mounjaro approvals, Drugs@FDA (openFDA)
This page reports what the Mounjaro label says and does not give advice. Each percentage is a trial-group average, not a prediction for a single person.